PF-610355

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-610355
Drug Alias NamePF-610PF-610355PF-00610355
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveLung Diseases, ObstructiveLung Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveLung Diseases, ObstructiveLung Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia